Compare HSBC Holdings plc (HSBC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs 10X Genomics Inc — how do they compare? HSBC Holdings plc trades at $92.98 (market cap $311.92B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: HSBC Holdings plc is far larger — about 31× 10X Genomics Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and 10X Genomics Inc for 91 Days on average.
| HSBC | TXG | |
|---|---|---|
Market Cap | $311.92B | $10.07B |
Volume | 3,546,658 | 5,657,286 |
Sector | Financials | Health |
52-Week High | $107.86 | $97.74 |
52-Week Low | $65.67 | $11.48 |
Typical Hold Time | 36 Days | 91 Days |
Enterprise Value | $222.19B | $9.59B |
Dividend Yield | 4.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.98, down 0.78% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and ROE of 12.44%. Recent earnings were mixed, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. News highlights strategic moves like expanding in India equity broking and enhancing U.S. Premier services, while the CFO plans to step down in 2027.
The outlook is cautiously optimistic given strong profitability and growth initiatives, but risks include execution challenges from business restructuring and macroeconomic headwinds. Analysts are divided with 38.1% buy ratings, suggesting potential upside if earnings momentum improves, though bearish technicals warrant monitoring near support at $91.
TXG trades at $80.65, up 5.98% on the day, showing strong recent momentum despite a bearish technical signal. The company reported revenue of $642.82M for 2025 with a gross margin of 70.03%, but remains unprofitable with a net loss of $43.54M. Recent news highlights the launch of the Atera spatial biology platform and a patent victory, signaling innovation and competitive strength. Analyst consensus is mixed with a $74.30 price target below the current price, indicating caution on valuation.
The outlook for TXG hinges on commercial execution of new products like Atera to drive revenue growth and a path to profitability. Investment opportunity lies in its leading technology platform and expanding market demand in genomics. Key risks include persistent losses, high valuation multiples, and competitive pressures in the life sciences tools sector. The stock's recent rally faces a test near technical resistance at $81.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
